Profile

Cover photo
Advaxis, Inc.
25 followers|10,938 views
AboutPostsPhotosYouTube

Stream

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Prices $53 Million Public Offering of Common Stock http://bit.ly/1IrcKXj
PRINCETON, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced the pricing of its previously announced underwritten public offering of 2800000 shares of its common stock at a public offering price of $19.00 per ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has enhanced the Company's Lm-LLO cancer immunotherapy intellectual property portfolio with two USPTO patents addressing Advaxis's product candidates, ADXS-PSA and ADXS-HER2. Read the full press release here: http://bit.ly/1DT1sVh
ADXS-PSA Patent Covers a Recombinant Listeria Strain Encoded with Recombinant Fusion Peptide of KLK3 Peptide Linked to Non-KLK3 Peptide. ADXS-HER2 Patent Covers Method of Use in Treating HER2/Neu Expressing Tumors, Particularly Osteosarcoma, in Non-Human Animals and Companion Dogs ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Have you registered yet for Advaxis's Research Reception at the AACR Annual meeting? Join us on April 21, 2015 at 6:30 p.m. in Philadelphia: http://bit.ly/1IQOdsX
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis has been included to the Loncar Cancer Immunotherapy Index (LCINDX), the first professional index to track the transformational immunotherapy field within the biotechnology space. Based on current allocations and current share prices, Advaxis is the most heavily weighted stock in LCINDX. Find out more: http://bit.ly/1JvPtC5
PRINCETON, N.J., April 10, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its stock has been added to the Loncar Cancer Immunotherapy Index (LCINDX). Based on current allocations and current ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis is entering a clinical trial collaboration agreement with the Radiation Therapy Oncology Group (RTOG) Foundation to evaluate the safety and efficacy of Advaxis's lead cancer immunotherapy candidate, ADXS-HPV, in a pivotal Phase 2/3 anal cancer trial. http://bit.ly/1JfwsDW
Study Will be Conducted by NRG Oncology and Will Evaluate ADXS-HPV in Combination With Chemotherapy and Radiation in High-Risk, Locally Advanced Anal Cancer. PRINCETON, N.J., April 6, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will host an AACR Research Reception at The Ritz Carlton, Philadelphia on April 21, 2015 at 6:30 p.m. EST. Click now to register: http://bit.ly/1IQOdsX
1
Add a comment...
Have them in circles
25 people
Shanelle Russell's profile photo
ika Niniashvili's profile photo
Corsilo Japon's profile photo
Michael Higgins's profile photo
Steve D's profile photo
Bettina Lau's profile photo
Scott A's profile photo
David Miller's profile photo
jim dooley's profile photo

Advaxis, Inc.

Shared publicly  - 
 
Advaxis Announces Proposed Public Offering of Common Stock http://bit.ly/1IozBCF
PRINCETON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage cancer immunotherapy company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Advaxis expects to grant the underwriters a 30-day ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Data of three studies highlighting the survival outcomes and anti-tumor effects of Advaxis's proprietary Lm-LLO cancer immunotherapy technology was announced at the 2015 American Association for Cancer Research (AACR) Annual Meeting this week. "The data presented at AACR demonstrate that our Lm-LLO technology platform offers significant opportunity to address a number of cancer needs and indications,” stated Daniel O’Connor. http://bit.ly/1HfVmpd
ADXS-HPV Combined with Anti-OX40 or Anti-GITR Antibodies Demonstrates Tumor Growth Inhibition and Prolonged Survival in a Preclinical Study. ADXS-HER2 in Combination with Palliative Radiation Delays Tumor Progression, Prolongs Overall Survival and Maintains Limb Function in Preliminary Data from ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will host an AACR Research Reception at The Ritz Carlton, Philadelphia on April 21, 2015 at 6:30 p.m. EST. Click now to register: http://bit.ly/1IQOdsX
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis and Merck have initiated enrollment in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA and KEYTRUDA® in patients with previously treated, metastatic castration-resistant prostate cancer. The clinical trial, KEYNOTE-046, is the first-in-human study of ADXS-PSA and the second trial evaluating Keytruda for prostate cancer. http://bit.ly/1GoTmdK
KEYNOTE-046 is the Second Trial Initiated to Evaluate KEYTRUDA, and the First-in-Human Study of ADXS-PSA, for Prostate Cancer. PRINCETON, N.J. and KENILWORTH, N.J., April 8, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer ...
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Have you registered yet for Advaxis's Research Reception at the AACR Annual meeting? Join us on April 21, 2015 at 6:30 p.m. in Philadelphia: http://bit.ly/1IQOdsX
1
Add a comment...

Advaxis, Inc.

Shared publicly  - 
 
Advaxis will be hosting an American Association for Cancer Research (AACR) Annual Research Reception on Tuesday, April 21, 2015 at 6:30 p.m. EST. During the event, Advaxis's senior management team and renowned thought leaders will discuss the Company's Lm-LLO immunotherapy platform and clinical programs. Find out more:
1
Add a comment...
People
Have them in circles
25 people
Shanelle Russell's profile photo
ika Niniashvili's profile photo
Corsilo Japon's profile photo
Michael Higgins's profile photo
Steve D's profile photo
Bettina Lau's profile photo
Scott A's profile photo
David Miller's profile photo
jim dooley's profile photo
Contact Information
Contact info
Phone
609-452-9813
Address
305 College Rd E‎ Princeton, NJ 08540
Story
Tagline
Advaxis is a biotechnology company developing the next generation of cancer immunotherapies.
Introduction

Advaxis (NASDAQ: ADXS) is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.